Elanco Animal Health Incorporated Quick Ratio (ELAN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Elanco Animal Health Incorporated  (NYSE: ELAN)

Elanco Animal Health Incorporated's Quick Ratio

ELAN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.26 below Elanco Animal Health Incorporated's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 407 other companies have achieved higher Quick Ratio than Elanco Animal Health Incorporated in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 2755 to 3095.

Explain Quick Ratio?
How much Cash & cash equivalents ELAN´s has?
What are ELAN´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ELAN/financial-strength
https://api.csimarket.com/api/v1/companies/ELAN/fundamentals
https://api.csimarket.com/api/v1/companies/ELAN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ELAN Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 65.62 %
Y / Y Cash & cash equivalent Change -7.92 %
Quick Ratio MRQ 0.26
ELAN's Total Ranking # 3095
Seq. Current Liabilities Change -3.51 %
Seq. Cash & cash equivalent Change -12.26 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 408
Healthcare Sector # 789
Overall Market # 3095


Quick Ratio Statistics
High Average Low
2.34 0.57 0.25
(Mar 31 2020)   (Dec 31 2022)




Financial Statements
Elanco Animal Health Incorporated's Current Liabilities $ 1,787 Millions Visit ELAN's Balance sheet
Elanco Animal Health Incorporated's Cash & cash equivalent $ 465 Millions Visit ELAN's Balance sheet
Source of ELAN's Sales Visit ELAN's Sales by Geography


Cumulative Elanco Animal Health Incorporated's Quick Ratio

ELAN's Quick Ratio for the trailling 12 Months

ELAN Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 50.66 %
Y / Y Cash & cash equivalent TTM Growth -1.55 %
Quick Ratio TTM 0.32
Total Ranking TTM # 2398
Seq. Current Liabilities TTM Growth 13.17 %
Seq. Cash & cash equivalent TTM Growth -1.99 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $1,787.00 millions, cumulative Quick Ratio decreased to 0.32 below the Elanco Animal Health Incorporated average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Elanco Animal Health Incorporated. While Quick Ratio overall ranking has improved so far to 4076, from total ranking during the twelve months ending second quarter 2026 at 4086.

Explain Quick Ratio?
How much Cash & cash equivalents ELAN´s has?
What are ELAN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 443
Healthcare Sector # 908
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.04 0.39 0.24
(Jun 30 2020)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Ionis Pharmaceuticals Inc   0.68 $ 296.303  Millions$ 435.292  Millions
Liquidia Corporation  0.68 $ 396.091  Millions$ 585.397  Millions
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions
Zoetis Inc   0.57 $ 1,533.000  Millions$ 2,682.000  Millions
Organon and Co   0.55 $ 1,455.000  Millions$ 2,652.000  Millions
Medicus Pharma Ltd   0.52 $ 5.020  Millions$ 9.743  Millions
Gossamer Bio Inc   0.51 $ 51.189  Millions$ 99.945  Millions
Bausch Health Companies Inc   0.51 $ 2,485.000  Millions$ 4,895.000  Millions
Neonc Technologies Holdings Inc   0.49 $ 10.966  Millions$ 22.241  Millions
Inovio Pharmaceuticals Inc   0.48 $ 49.786  Millions$ 102.842  Millions
Avenue Therapeutics Inc   0.47 $ 1.520  Millions$ 3.210  Millions
Royalty Pharma Plc  0.46 $ 544.857  Millions$ 1,179.003  Millions
Zymeworks Inc   0.45 $ 100.464  Millions$ 223.931  Millions
Organogenesis Holdings Inc   0.45 $ 21.326  Millions$ 47.649  Millions
Inmed Pharmaceuticals Inc  0.43 $ 1.140  Millions$ 2.673  Millions
Kiniksa Pharmaceuticals International Plc  0.43 $ 81.660  Millions$ 191.855  Millions
Syndax Pharmaceuticals Inc   0.40 $ 146.094  Millions$ 361.833  Millions
Vanda Pharmaceuticals Inc   0.40 $ 62.038  Millions$ 154.980  Millions
Kura Oncology Inc   0.39 $ 57.937  Millions$ 148.730  Millions
Ultragenyx Pharmaceutical Inc   0.39 $ 150.000  Millions$ 389.000  Millions
Biomarin Pharmaceutical Inc  0.38 $ 736.007  Millions$ 1,913.942  Millions
Earth Science Tech Inc   0.38 $ 1.009  Millions$ 2.639  Millions
Aurinia Pharmaceuticals Inc   0.36 $ 45.792  Millions$ 127.629  Millions
Merck and Co Inc   0.34 $ 9,650.000  Millions$ 28,801.000  Millions
Cytodyn inc   0.33 $ 16.359  Millions$ 49.700  Millions

Date modified: 2026-11-07T13:23:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.